ArticleJournal of inflammation research2026
The Predictive Value of Systemic Inflammatory Markers from Failed Single-Dose Methotrexate Therapy in Tubal Ectopic Pregnancy: A Retrospective Single-Center Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Assessing the systemic inflammatory markers as a prognostic factor for resistance to methotrexate in ectopic pregnancy. Methods: This retrospective cohort study included 412 cases of patients with tubal ectopic pregnancy who received single-dose methotrexate (MTX) therapy at the Obstetrics and Gynecology Hospital affiliated with Tongji University from January 2019 to January 2024. Participants were categorized into successful and unsuccessful cohorts according to single-dose methotrexate treatment. Systemic inflammatory parameters, particularly lymphocyte counts, NLR, and β-hCG, were collected for each case from blood tests. Regression analyses were employed to pinpoint independent risk factors linked to treatment failure. A nomogram was developed to represent these relationships. The model's ability to distinguish outcomes was assessed by the area under the curve (AUC). Results: The research sample included 302 successful individuals and 110 unsuccessful ones. Compared with baseline, NLR decreased by less than 40.3% on Day 4 (95% [CI] 1.26-3.12), while β-hCG levels rose on Day 4 (95% CI: 1.14-2.80). HCG levels >342.25 mIU/mL on day 0 (95% CI 1.74-4.40) and lymphocyte counts >2.165 × 10 Conclusion: Among systemic inflammatory markers, NLR and lymphocyte levels significantly correlate with treatment failure. Incorporating them with β-hCG into the model enhances risk predictive capability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.